{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:21Z","timestamp":1777984341683,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["WSW\u2010064"],"award-info":[{"award-number":["WSW\u2010064"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions of China","award":["19KJB310001"],"award-info":[{"award-number":["19KJB310001"]}]},{"name":"Postdoctoral Research Funding Project in Jiangsu Province","award":["2021K447C"],"award-info":[{"award-number":["2021K447C"]}]},{"name":"Second Round of Xuzhou Medical Leading Talents Training Project","award":["XWRCHT20210027"],"award-info":[{"award-number":["XWRCHT20210027"]}]},{"name":"The Science and Technology Planning Project of Traditional Chinese Medicine of Jiangsu","award":["YB2020050"],"award-info":[{"award-number":["YB2020050"]}]},{"name":"Key Medical Research Projects of Jiangsu Provincial Health Commission","award":["K2024040"],"award-info":[{"award-number":["K2024040"]}]},{"name":"National Nature Science Foundation of China Youth Project","award":["81502193"],"award-info":[{"award-number":["81502193"]}]},{"name":"Jiangsu Provincial Graduate Research and Practice Innovation Program","award":["KYCX24_3070"],"award-info":[{"award-number":["KYCX24_3070"]}]},{"name":"Construction Project of High Level Hospital of Jiangsu Province","award":["LCZX202407"],"award-info":[{"award-number":["LCZX202407"]}]},{"name":"Jiangsu Province Postdoctoral Innovation Practice Base Medical Science and Technology Innovation Project","award":["SRYKTH202402"],"award-info":[{"award-number":["SRYKTH202402"]}]},{"name":"Innovation and entrepreneurship projects at the Xuzhou Medical University Science and Technology Park","award":["CXCYYB202413"],"award-info":[{"award-number":["CXCYYB202413"]}]},{"name":"Research project on the \u201cPairing Assistance\u201d initiative at the Affiliated Hospital of Xuzhou Medical University","award":["FXJDBF2024104"],"award-info":[{"award-number":["FXJDBF2024104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15806-9","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:36:37Z","timestamp":1772246197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"15806_CR1","doi-asserted-by":"publisher","unstructured":"Cheng L, Lopez-Beltran A, Bostwick DG. Bladder pathology. Wiley-Blackwell; 2012. https:\/\/doi.org\/10.1002\/9781118275436.","DOI":"10.1002\/9781118275436"},{"key":"15806_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"15806_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, et al. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5:628\u201339. https:\/\/doi.org\/10.1016\/j.euo.2022.10.003.","journal-title":"Eur Urol Oncol"},{"key":"15806_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.21.02928","volume":"40","author":"GP Sonpavde","year":"2022","unstructured":"Sonpavde GP, Mouw KW, Mossanen M. Therapy for muscle-invasive urothelial carcinoma: controversies and dilemmas. J Clin Oncol. 2022;40:1275\u201380. https:\/\/doi.org\/10.1200\/JCO.21.02928.","journal-title":"J Clin Oncol"},{"key":"15806_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/jpm13050756","volume":"13","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Mishra SK, Cheng L. Precision medicine in bladder cancer: present challenges and future directions. J Pers Med. 2023;13:756. https:\/\/doi.org\/10.3390\/jpm13050756.","journal-title":"J Pers Med"},{"key":"15806_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.hoc.2021.02.006","volume":"35","author":"DJ Konieczkowski","year":"2021","unstructured":"Konieczkowski DJ, Efstathiou JA, Mouw KW. Contemporary and emerging approaches to bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2021;35:567\u201384. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.006.","journal-title":"Hematol Oncol Clin North Am"},{"key":"15806_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-022-01802-3","volume":"82","author":"A Tripathi","year":"2022","unstructured":"Tripathi A, MacDougall K, Sonpavde GP. Therapeutic landscape beyond immunotherapy in advanced urothelial carcinoma: moving past the checkpoint. Drugs. 2022;82:1649\u201362. https:\/\/doi.org\/10.1007\/s40265-022-01802-3.","journal-title":"Drugs"},{"key":"15806_CR8","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810. https:\/\/doi.org\/10.1016\/S0140-6736(16)30512-8.","journal-title":"Lancet"},{"key":"15806_CR9","doi-asserted-by":"publisher","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol 2022;81:50\u201361.https:\/\/doi.org\/10.1016\/j.eururo.2021.09.028","DOI":"10.1016\/j.eururo.2021.09.028"},{"issue":"2","key":"15806_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"15806_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.urology.2024.08.067","volume":"194","author":"S Kronstedt","year":"2024","unstructured":"Kronstedt S, Saffati G, Hinojosa-Gonzalez DE, et al. Early adjuvant chemotherapy improves survival in muscle invasive bladder cancer: a systematic review and meta-analysis. Urology. 2024;194:289\u201394. https:\/\/doi.org\/10.1016\/j.urology.2024.08.067.","journal-title":"Urology"},{"issue":"6","key":"15806_CR12","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.4103\/0973-1482.188434","volume":"14","author":"C Yu","year":"2018","unstructured":"Yu C, Hequn C, Jinbo C, Feng Z, Xiongbing Z, Jian D. Gemcitabine\/cisplatin versus methotrexate\/vinblastine\/doxorubicin\/cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2018;14(6):1260\u20135. https:\/\/doi.org\/10.4103\/0973-1482.188434.","journal-title":"J Cancer Res Ther"},{"issue":"28","key":"15806_CR13","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose TL, Harrison MR, Deal AM, et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J Clin Oncol. 2021;39(28):3140\u20138. https:\/\/doi.org\/10.1200\/JCO.21.01003.","journal-title":"J Clin Oncol"},{"issue":"10232","key":"15806_CR14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3.","journal-title":"Lancet"},{"issue":"4","key":"15806_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrclinonc.2016.188","volume":"14","author":"SA Funt","year":"2017","unstructured":"Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017;14(4):221\u201334. https:\/\/doi.org\/10.1038\/nrclinonc.2016.188.","journal-title":"Nat Rev Clin Oncol"},{"key":"15806_CR16","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. London: NICE; 2022 Jun 29 [updated 2023 Mar 24]. (NICE guideline NG28). Available from: https:\/\/www.nice.org.uk\/guidance\/ng28"},{"key":"15806_CR17","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/JME-12-0007","volume":"48","author":"RJ Dowling","year":"2012","unstructured":"Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31\u201343.","journal-title":"J Mol Endocrinol"},{"key":"15806_CR18","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","volume":"67","author":"RJ Dowling","year":"2007","unstructured":"Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67:10804\u201312.","journal-title":"Cancer Res"},{"key":"15806_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00592-011-0276-y","volume":"48","author":"E Fidan","year":"2011","unstructured":"Fidan E, Onder Ersoz H, Yilmaz M, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 2011;48:297\u2013302.","journal-title":"Acta Diabetol"},{"key":"15806_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1741-7015-9-33","volume":"9","author":"RJ Dowling","year":"2011","unstructured":"Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.","journal-title":"BMC Med"},{"issue":"12","key":"15806_CR21","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","volume":"27","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdw410.","journal-title":"Ann Oncol"},{"issue":"1","key":"15806_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-016-3037-3","volume":"78","author":"HH Zhang","year":"2016","unstructured":"Zhang HH, Guo XL. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016;78(1):13\u201326. https:\/\/doi.org\/10.1007\/s00280-016-3037-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"15806_CR23","doi-asserted-by":"publisher","first-page":"24603","DOI":"10.3390\/ijms141224603","volume":"14","author":"T Zhang","year":"2013","unstructured":"Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci. 2013;14:24603\u201318.","journal-title":"Int J Mol Sci"},{"key":"15806_CR24","first-page":"663","volume":"70","author":"N Chomani\u010dov\u00e1","year":"2021","unstructured":"Chomani\u010dov\u00e1 N, Gazova A, Adami\u010dkov\u00e1 A, Val\u00e1\u0161kov\u00e1 S, Kyselovi\u010d J. The role of AMPK\/mTOR signaling pathway in anticancer activity of metformin. Physiol Res. 2021;70:663\u201373.","journal-title":"Physiol Res"},{"key":"15806_CR25","doi-asserted-by":"crossref","unstructured":"Shen, Z.-f.; Xue, D.; Wang, K.; Zhang, F.; Shi, J.; Jia, B.; Yang, D.; Zhang, Q.-j.; Zhang, S.; Jiang, H.; Luo, D.; Li, X.; Zhong, Q.; Zhang, J.; Peng, Z.; Han, Y.; Sima, C.; He, X.; Hao, L. Metformin Exerts an Antitumor Effect by Inhibiting Bladder Cancer Cell Migration and Growth, and Promoting Apoptosis Through the PI3K\/AKT\/mTOR Pathway. BMC Urol. 2021, 21, Article 24.","DOI":"10.21203\/rs.3.rs-846120\/v1"},{"key":"15806_CR26","first-page":"1143","volume":"38","author":"F Wang","year":"2017","unstructured":"Wang F, Liu W, Xu X, Yang Y, Yi Q, Guo F, et al. Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK\/mTOR pathway in human bladder cancer cells. Oncol Rep. 2017;38:1143\u201351.","journal-title":"Oncol Rep"},{"key":"15806_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109273","volume":"330","author":"X Zhou","year":"2020","unstructured":"Zhou X, Chen YX, Wang F, Wu H, Zhang Y, Liu J, et al. Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. Chem Biol Interact. 2020;330:109273.","journal-title":"Chem Biol Interact"},{"key":"15806_CR28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22117","author":"Y Xiao","year":"2017","unstructured":"Xiao Y, Zheng L, Mei Z, Xu C, Liu C, Chu X, et al. The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.22117.","journal-title":"Oncotarget"},{"issue":"8","key":"15806_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082013","volume":"12","author":"W-S Chung","year":"2020","unstructured":"Chung W-S, Le P-H, Kuo C-J, Chen T-H, Kuo C-F, Chiou M-J, et al. Impact of metformin use on survival in patients with gastric cancer and diabetes mellitus following gastrectomy. Cancers. 2020;12(8):2013.","journal-title":"Cancers"},{"issue":"4","key":"15806_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.11622\/smedj.2020121","volume":"63","author":"Z Wang","year":"2020","unstructured":"Wang Z, Ong W, Tong S, Sng J, Lata R, Mahendran R, et al. Beyond diabetes mellitus: role of metformin in non-muscle invasive bladder cancer. Singapore Med J. 2020;63(4):209\u201315.","journal-title":"Singapore Med J"},{"key":"15806_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.07.006","author":"M Rieken","year":"2014","unstructured":"Rieken M, Xylinas E, Kluth L, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol. 2014. https:\/\/doi.org\/10.1016\/j.urolonc.2013.07.006.","journal-title":"Urol Oncol"},{"issue":"8","key":"15806_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/bju.12448","volume":"112","author":"M Rieken","year":"2013","unstructured":"Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 2013;112(8):1105\u201312. https:\/\/doi.org\/10.1111\/bju.12448.","journal-title":"BJU Int"},{"issue":"30","key":"15806_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011596","volume":"97","author":"J Hu","year":"2018","unstructured":"Hu J, Chen J, Cui Y, Zhu Y, Ren W, Zhou X, et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients. Medicine. 2018;97(30):e11596.","journal-title":"Medicine"},{"key":"15806_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01083-8","volume":"22","author":"X Ren","year":"2022","unstructured":"Ren X, Tian Y, Wang Z, Wang J, Li X, Yin Y, et al. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study. BMC Urol. 2022;22:108.","journal-title":"BMC Urol"},{"key":"15806_CR35","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/DDDT.S353898","volume":"16","author":"Q Yang","year":"2022","unstructured":"Yang Q, Nie Y, Cai M-B, Li Z, Zhu H, Tan Y-R. Gemcitabine combined with cisplatin has a better effect in the treatment of recurrent\/metastatic advanced nasopharyngeal carcinoma. Drug Des Devel Ther. 2022;16:1145\u201354.","journal-title":"Drug Des Devel Ther"},{"key":"15806_CR36","doi-asserted-by":"crossref","unstructured":"Wissing, M.; O\u2019Flaherty, A.; Dragomir, A.; Tanguay, S.; Kassouf, W.; Aprikian, A. Chronic Prednisone, Metformin, and Nonsteroidal Anti-Inflammatory Drug Use and Clinical Outcome in a Cohort of Bladder Cancer Patients Undergoing Radical Cystectomy in Qu\u00e9bec, Canada. BMC Urol. 2023;23(1), Article 35.","DOI":"10.1186\/s12894-023-01287-6"},{"issue":"3","key":"15806_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/COC.0000000000000512","volume":"42","author":"M Nayan","year":"2019","unstructured":"Nayan M, Punjani N, Juurlink DN, Finelli A, Austin PC, Kulkarni GS, et al. Metformin use and kidney cancer survival outcomes: a systematic review and meta-analysis. Am J Clin Oncol. 2019;42(3):275\u201384.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"15806_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1186\/s12885-019-6346-1","volume":"19","author":"RJ Molenaar","year":"2019","unstructured":"Molenaar RJ, van Hattum JW, Brummelhuis I, Oddens J, Savci-Heijink CD, Boev\u00e9 E, et al. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer. 2019;19(1):1137.","journal-title":"BMC Cancer"},{"issue":"2","key":"15806_CR39","first-page":"11621","volume":"7","author":"B Hamedi","year":"2018","unstructured":"Hamedi B, Khalili A, Roozmeh S, Namazi G, Saraf Z. Combination of metformin and chemotherapy decreases the recurrence rates of epithelial ovarian cancers: a randomized clinical trial. Iran J Cancer Manag. 2018;7(2):11621.","journal-title":"Iran J Cancer Manag"},{"key":"15806_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.breast.2019.08.003","volume":"48","author":"I Pimentel","year":"2019","unstructured":"Pimentel I, Lohmann AE, Ennis M, Dowling RJO, Cescon DW, Elser C, et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast. 2019;48:17\u201323.","journal-title":"Breast"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15806-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15806-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:23:11Z","timestamp":1775812991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15806-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15806"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15806-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5022906\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of The Affiliated Hospital of Xuzhou Medical University (XYFY2022-KL340). Since the study involved the review of existing medical records and did not require direct patient contact or intervention, the need for informed consent from individual patients was waived by the ethics committee. However, all patient data were anonymized to ensure patient confidentiality and privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent participate"}},{"value":"The authors confirm that all authors have reviewed and approved the final version of the manuscript for publication. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. There are no conflicts of interest to disclose that could potentially influence the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}